sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industryleading, platform-agnostic genome analysis software solution and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For mor ...

At a sponsored scientific workshop titled "Revolutionizing hematological disease: unraveling genomic mysteries with optical genome mapping," Su Yang, CG (ASCP), from The University of Texas MD Anderson Cancer Center, will present cancer research case studies that demonstrate OGM's ability to detect structural abnormalities in hematological samples at high sensitivity and resolution. | --- | --- | --- | --- | |---------------------|----------------------------------------------------------------------------- ...

As part of a sponsored session titled "High-resolution genome integrity assessment in stem cell therapy development with optical genome mapping," three experts will discuss the critical role of OGM in assessing the genome integrity and off-target events in engineered cells, specifically within the context of stem cell research. Presentations will cover OGM's utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profil ...

The establishment of a new Category I CPT code for OGM implies that it has met the standards of acceptance by the medical community, in contrast to a Category III code, which is generally applied to emerging technologies. As part of the application review process, the panel collects input from stakeholders across the health care community to ensure CPT content reflects the coding and data-driven demands of modern health care. About Bionano Laboratories: About Bionano For more information, visit www.bionano. ...

Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth. Some face challenges that make them less attractive investments. Three healthcare stocks, in particular, should be approached with caution. Despite the initial appeal, these firms may not provide the best value for money in the market. Their issues range from regulatory setbacks to financial instability, making them risky choices for investo ...

SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024. This new financing rein ...

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company's VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematol ...

Start Time: 16:30 January 1, 0000 4:27 PM ET Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2024 Earnings Conference Call May 08, 2024, 16:30 PM ET Company Participants Erik Holmlin - President and CEO Gülsen Kama - CFO David Holmes - IR Conference Call Participants Sung Ji Nam - Scotiabank Operator Good day, and welcome to the Bionano First Quarter 2024 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from Investor Relations. P ...

Table of Contents ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38613 _________________________________________________________ Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Stock Market, LLC Large accelerated filer ☐ Accelerated filer ...

• Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 • Conference call today, May 8 , 2024, at 4:30 PM ET th Recent Highlights • Installed base of OGM systems totaled 347 at the end of the first quarter of 2024, which represents a 34% increase over the 259 installed systems reported at the end of the first quarter of 2023. ◦ In a study on hereditary breast and ovarian cancer syndrome, researchers used OGM to detect SVs in tumors that may be linked to mutated genes and altered si ...